BI 3031185

DRUG5 trials

Sponsors

Boehringer Ingelheim

Conditions

Attention Deficit Hyperactivity DisorderBorderline Personality DisorderHealthy

Phase 1

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

CompletedNCT06255340

Boehringer IngelheimHealthy

Start: 2024-03-11End: 2024-08-28Updated: 2024-11-13

A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women

SuspendedNCT06916702

Boehringer IngelheimHealthy

Start: 2025-04-07End: 2026-10-13Target: 100Updated: 2026-08-19

A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

CompletedNCT07001475

Boehringer IngelheimAttention Deficit Hyperactivity Disorder, Borderline Personality Disorder

Start: 2025-08-12End: 2026-08-06Updated: 2026-08-10

A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood

CompletedNCT07211425

Boehringer IngelheimHealthy

Start: 2025-10-08End: 2026-01-21Updated: 2026-02-04

A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the Blood

SuspendedNCT07656792

Boehringer IngelheimHealthy

Start: 2026-07-17End: 2026-11-26Target: 36Updated: 2026-08-19